Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Kanerva

Showing results (11-20 of 124) with videos related to

Pageof 13
Sort By:
International Journal of Cancer|December 26, 2022
Long-term survival trends in solid cancers in the Nordic countries marking timing of improvementsKari Hemminki, Asta Försti, Vaclav Liska, et al.
International Journal of Cancer|February 23, 2007
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancerTuuli Ranki, Merja Särkioja, Tanja Hakkarainen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 4, 2025
PPP2R1A mutation status as a predictive and prognostic factor in molecularly characterized endometrial carcinoma: a cohort studyMasuma Khatun, Annukka Pasanen, Anna Kanerva, et al.
The Journal of Gene Medicine|March 15, 2008
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificityMerja Särkioja, Tanja Hakkarainen, Minna Eriksson, et al.
Cells|April 1, 2020
TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological SignalingCamilla Heiniö, Riikka Havunen, Joao Santos, et al.
Molecular Cancer Therapeutics|July 27, 2016
Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive CancerIlkka Liikanen, Siri Tähtinen, Kilian Guse, et al.
Gynecologic Oncology|October 24, 2007
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancerMari Raki, Merja Särkioja, Renee A Desmond, et al.
The Journal of Gene Medicine|August 12, 2009
Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cellsAnniina Koski, Maria Rajecki, Kilian Guse, et al.
Molecular Therapy Oncolytics|July 11, 2018
Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic ImmunotherapyOtto Hemminki, Minna Oksanen, Kristian Taipale, et al.
Cancer Research|February 20, 2003
Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expressionAkseli Hemminki, Anna Kanerva, Bin Liu, et al.
Pageof 13

Showing results (11-20 of 124) with videos related to

Sort By:
Pageof 13
International Journal of Cancer|December 26, 2022
Long-term survival trends in solid cancers in the Nordic countries marking timing of improvementsKari Hemminki, Asta Försti, Vaclav Liska, et al.
International Journal of Cancer|February 23, 2007
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancerTuuli Ranki, Merja Särkioja, Tanja Hakkarainen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 4, 2025
PPP2R1A mutation status as a predictive and prognostic factor in molecularly characterized endometrial carcinoma: a cohort studyMasuma Khatun, Annukka Pasanen, Anna Kanerva, et al.
The Journal of Gene Medicine|March 15, 2008
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificityMerja Särkioja, Tanja Hakkarainen, Minna Eriksson, et al.
Cells|April 1, 2020
TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological SignalingCamilla Heiniö, Riikka Havunen, Joao Santos, et al.
Molecular Cancer Therapeutics|July 27, 2016
Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive CancerIlkka Liikanen, Siri Tähtinen, Kilian Guse, et al.
Gynecologic Oncology|October 24, 2007
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancerMari Raki, Merja Särkioja, Renee A Desmond, et al.
The Journal of Gene Medicine|August 12, 2009
Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cellsAnniina Koski, Maria Rajecki, Kilian Guse, et al.
Molecular Therapy Oncolytics|July 11, 2018
Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic ImmunotherapyOtto Hemminki, Minna Oksanen, Kristian Taipale, et al.
Cancer Research|February 20, 2003
Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expressionAkseli Hemminki, Anna Kanerva, Bin Liu, et al.
Pageof 13